Application of macranthoidin A in preparation of product for promoting skin wound repair and regeneration

By using grey felt honeysuckle saponin to promote the proliferation of fibroblasts and vascular endothelial cells and collagen secretion, the problem of low skin trauma repair efficiency in the prior art is solved, and high efficiency is achieved on skin trauma and diabetes-inducing wounds repair.

CN119074744AActive Publication Date: 2024-12-06JINAN UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411174874.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-06
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

There are no effective drugs in the prior art that can promote the repair and regeneration of skin trauma, especially the repair of chronic wounds and difficult-to-healthy wounds in diabetes.

Method used

Using Macranthoidin A as a small molecule compound, it promotes the proliferation, migration and collagen secretion of fibroblasts and vascular endothelial cells, and promotes the repair and regeneration of skin trauma. It is suitable for the preparation of medical and skin care products. .

Benefits of technology

Gray felt honeysuckle saponin significantly accelerates wound healing, promotes blood vessels and collagen production, reduces the secretion of inflammatory substances, and is safe and effective for repairing skin trauma and diabetes-inducing wounds, without obvious acute toxic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074744A_ABST
    Figure CN119074744A_ABST
Patent Text Reader

Abstract

The invention discloses an application of macranthoidin A in preparation of a product for promoting skin wound repair and regeneration. Experiments find that the macranthoidin A can promote proliferation and migration of fibroblasts and vascular endothelial cells, promote lumen formation of the vascular endothelial cells and promote the fibroblasts to secrete I-type collagen, can accelerate wound healing and promote generation of more blood vessels and collagen, and has a good application prospect. The traditional Chinese medicine composition has the functions of promoting skin wound repair and treating chronic ulcers, and provides an effective way for skin wound repair and regeneration, especially for the repair and regeneration of refractory wounds of diabetes mellitus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of drug development for treating human skin wound repair, and in particular to application of Lonicera japonica saponin A in preparing products promoting skin wound repair and regeneration. Background Art

[0002] Skin is the largest organ in the human body. It is not only a protective barrier for the body, but also participates in a variety of physiological functions. When the skin suffers trauma, such as cuts, abrasions or burns, the body initiates a series of complex biological processes to repair the damage, a process called wound healing. Wound healing is a multi-stage continuous process, which mainly includes four main stages: hemostasis, inflammation, proliferation and remodeling. Throughout the healing process, multiple cells, growth factors, cytokines and molecular pathways work together to ensure that the wound can be effectively closed and restore function. Among them, vascular endothelial cells (HUVEC cells) and fibroblasts (HSF cells) play a very important role. However, this process may be affected by a variety of factors, including nutritional status, age, chronic diseases, infection and wound cleanliness, all of which may delay healing or lead to poor healing. Therefore, the discovery of drugs that promote wound healing is very valuable.

[0003] Natural small molecule compounds are low molecular weight compounds with biological activity extracted from various natural sources. The sources of these compounds include plants, microorganisms and animals. In recent years, the application and development of small molecule natural compounds in wound healing and tissue repair have been widely explored. At present, natural compounds such as curcumin, resveratrol, tea polyphenols and quercetin, which have been widely studied, have been shown to have anti-inflammatory, antioxidant and regenerative effects.

[0004] Macranthoidin A (MaA for short) has a molecular weight of 1237.38 and a structural formula as shown in Formula I. It is an orally active saponin extracted from honeysuckle, has anti-inflammatory activity, and has a protective effect on liver damage caused by acetaminophen, cadmium and carbon tetrachloride, and has a significant inhibitory effect on the swelling of croton oil. However, so far, it has not been disclosed that maranthoidin A can be used to promote the repair process of skin wounds.

[0005] Summary of the invention

[0006] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide an application of Lonicera japonica saponin A in the preparation of products promoting skin wound repair and regeneration.

[0007] The purpose of the present invention is achieved through the following technical solutions:

[0008] Application of honeysuckle saponin A in preparing products promoting skin wound repair and regeneration.

[0009] The promotion of skin wound repair and regeneration includes promoting the repair and regeneration of skin cells (tissues) after wounding, and promoting the repair and regeneration of chronic wounds (promoting the healing of chronic wounds).

[0010] The chronic wounds include diabetic refractory wounds, such as diabetic refractory ulcers and the like.

[0011] The Lonicera japonica saponin A (a small molecule compound) can promote the repair and regeneration of skin wounds (including chronic wounds, refractory diabetic wounds, etc.) by promoting the proliferation and migration of fibroblasts, the proliferation and migration of vascular endothelial cells, the lumen formation of vascular endothelial cells, and the secretion of type I collagen by fibroblasts.

[0012] The fibroblasts include human fibroblasts.

[0013] The vascular endothelial cells include human vascular endothelial cells.

[0014] The blood vessels include capillaries.

[0015] The use concentration of the honeysuckle saponin A is 0.1-15 μmol / L.

[0016] The products include medical products (pharmaceutical products), skin care products or cosmetics.

[0017] The medical products include medicines and the like.

[0018] The product can be prepared into various dosage forms by conventional methods in the art, and the preparation types include solutions, lyophilized preparations, emulsions, creams, gels, facial masks or dressings, etc.

[0019] Compared with the prior art, the present invention has the following advantages and effects:

[0020] (1) The present invention found through in vitro cell experiments, namely, CCK-8, EdU, clone formation and Transwell experiments that the addition of Lonicera japonica saponin A can promote the proliferation and migration of HUVEC cells and HSF cells. The results of the HUVEC cell tube formation experiment showed that Lonicera japonica saponin A has the effect of promoting angiogenesis. The results of the ELISA experiment showed that the type I collagen secretion content of HSF cells increased with the addition of Lonicera japonica saponin A.

[0021] (2) The present invention found that Lonicera japonica saponin A exhibited good ability to promote angiogenesis and development through in vivo experiments, namely, in chicken embryo chorioallantoic membrane angiogenesis and transgenic zebrafish embryo vascular models; at the same time, it was verified in the back trauma models of normal mice and transgenic diabetic mice that Lonicera japonica saponin A could accelerate wound healing, promote the production of more blood vessels and collagen, reduce suppuration and the secretion of inflammatory substances, and had the ability and application value to promote wound repair and treat chronic ulcers.

[0022] (3) The present invention has conducted preliminary drug safety evaluation experiments and found that with the addition of Lonicera japonica saponin A, there are no obvious adverse reactions in zebrafish fry and mice; and by statistically analyzing the mortality rate and back deformity rate of zebrafish fry, it was found that Lonicera japonica saponin A has no obvious lethal or teratogenic side effects on the individual development of zebrafish fry. In addition, in the mouse back trauma model, the weight of the mice did not drop sharply, and the results of blood biochemistry showed that the liver injury parameters did not change significantly, and the tissue sections of the heart, liver, spleen, lungs and kidneys were stained in normal morphology. The above results show that Lonicera japonica saponin A has no obvious acute toxic effects, that is, the small molecule compound Lonicera japonica saponin A can be used to prepare products that promote the repair and regeneration of skin trauma, the healing of chronic wounds, and the repair and regeneration of refractory diabetic wounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The figure is the result of promoting the growth and function of vascular cells and fibroblasts by using Lonicera japonica saponin A of gray felt hair; A is the effect of different concentrations of Lonicera japonica saponin A on the proliferation activity of HSF cells detected by EdU staining; B is the quantitative statistical graph of the effect of Lonicera japonica saponin A of gray felt hair on the proliferation activity of HSF cells; C is the enhancement effect of different concentrations of Lonicera japonica saponin A on the proliferation of HUVEC cells measured and compared by CCK-8 kit; D is the effect of Lonicera japonica saponin A on promoting the formation of cell clones of HUVEC cells and HSF cells evaluated by clone formation experiment; E is the ability of Lonicera japonica saponin A to enhance the migration of HUVEC and HSF cells detected by Transwell experiment; F is the ability of Lonicera japonica saponin A to promote the formation of tubes by vascular endothelial cells detected by in vitro tube formation test; G is the ability of Lonicera japonica saponin A to promote the secretion of type I collagen by HSF cells quantified by ELISA experiment.

[0024] Figure 2The figures show the results of promoting angiogenesis and development of chicken embryos and zebrafish by using Lonicera japonica saponin A at gradient concentrations; A shows a group of 8-day-old chicken embryos treated with Lonicera japonica saponin A at gradient concentrations, and the development of blood vessels was compared 48 hours later; B shows the calculation and comparison of blood vessel diameters; C shows the calculation and comparison of blood vessel coverage areas; D shows the calculation and comparison of the number of blood vessel branches; E shows the application of Lonicera japonica saponin A at gradient concentrations to newborn zebrafish with vascular endothelial cells labeled with GFP fluorescent protein, and the development of blood vessels was observed 48 hours later; F shows the statistics of blood vessel branches in the abdominal venous plexus; G shows the statistics of the number of new blood vessel protrusions at the end of the vascular plexus; H shows the acute toxicity of Lonicera japonica saponin A at gradient concentrations; and I shows the teratogenic effect of Lonicera japonica saponin A at gradient concentrations.

[0025] Figure 3 The figure is the result of promoting the repair of normal mouse skin wound by Lonicera japonica saponin A; A is a schematic diagram of the experimental process; B is modeling of dorsal skin wounds in healthy C57BL / 6J mice, which were treated with bFGF and different concentrations of Lonicera japonica saponin A, and the changes in wound area were observed from 0 to 4 days after modeling; C is an overlay showing the progress of wound repair (the middle number represents the proportion of wound area to modeling area on the 4th day); D is a statistical graph of wound area changes over time; E is a statistical graph of mouse weight during the experiment; F is Serum alanine aminotransferase (ALT) content (mice were sacrificed and blood was collected on the same day to reflect potential liver damage); G is the serum aspartate aminotransferase (AST) content (mice were sacrificed and blood was collected on the same day to reflect potential liver damage); H is the longitudinal section of the wound, H&E staining was used to distinguish the tissue morphology and cell density and the quantitative graph; I is the Sirius red staining to distinguish the collagen secretion and the quantitative graph (collagen is stained blue); J is the calculation of the number of CD31-labeled endothelial cells in the wound area by IHC staining and the quantitative graph.

[0026] Figure 4The figure is the result of promoting the repair of refractory wounds in diabetic mice by using Lonicera japonica saponin A; A is a schematic diagram of the experimental process; B is the treatment of bFGF and different concentrations of Lonicera japonica saponin A after surface wound modeling in BKS-db mice with diabetic background, and the changes in wound area were observed and counted within 0 to 12 days after modeling; C is a stacked statistical graph of the progress of wound repair (the central number indicates the proportion of wound area on the 12th day to the modeling area); D is the statistical change of wound area over time; E is the statistical graph of the body weight of diabetic mice during the experiment; F is the longitudinal sectioning of the wound, and H&E staining is used to distinguish tissue morphology and cell density; G is the labeling of collagen secretion by Masson staining (collagen is stained blue); H is the labeling of fibroblasts by Anti-αSMA mAb, and the number of labeled cells is counted; I is the labeling of vascular endothelial cells by Anti-CD31mAb, and the number of labeled cells is counted. DETAILED DESCRIPTION

[0027] The present invention will be described in further detail below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The test methods for which specific experimental conditions are not specified in the following examples are usually carried out according to conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, the reagents and raw materials used in the present invention can be obtained commercially.

[0028] Example 1

[0029] 1. Honeysuckle saponin A promotes the growth and function of vascular cells and fibroblasts

[0030] 1.1 EdU cell proliferation assay

[0031] Refer to the instructions of the Bio-Tech EdU Cell Proliferation Detection Kit to conduct the experiment. The process is as follows:

[0032] (1) HSF cells (ATCC) were fully digested and cell suspension was prepared. The number of cells was counted using a cell counter. After preliminary experiments, the appropriate cell inoculation amount was obtained and 1500 cells were evenly plated in each well of a 24-well plate.

[0033] (2) Cultured in a 37°C incubator for 24 h to allow cells to adhere. Prepare the required drug concentrations and add them to 96-well plates; the experiment was divided into 5 groups, with the experimental groups adding 2 μM, 4 μM, and 8 μM MaA, respectively, and the control group adding 500 IU basic fibroblast growth factor (bFGF) (purchased from Shanghai Qiangyao Biotechnology Co., Ltd.), and the blank control group (Blank, referred to as Bk) did not add drugs.

[0034] (3) When the cells grow to about 60% to 70%, prepare a 2x EdU working solution in serum-free culture medium (DMEM culture medium purchased from Gibco, USA) using 10mM EdU solution. Preheat the 2x EdU solution at 37°C, then add the 2x EdU solution to an equal volume of culture medium containing experimental cells to obtain a 1x EdU solution. That is, for a final concentration of 10μM EdU solution, half of the original culture medium can be replaced with fresh culture medium containing 20μM EdU.

[0035] (4) Place the treated cells in an incubator and continue incubating for 3 hours.

[0036] (5) After EdU labeling, the culture medium was removed and 500 μl of fixative (4% paraformaldehyde) was added to each well and fixed at room temperature for 15 min.

[0037] (6) Aspirate the fixative solution and wash the cells three times with 500 ul of washing solution (PBS buffer containing 3% (v / v) bovine serum albumin (BSA)) per well.

[0038] (7) Each well was incubated with 500 μl of permeabilization solution (PBS buffer containing 0.3% (v / v) Triton X-100) at room temperature for 10 to 15 min.

[0039] (8) Aspirate the permeabilization solution, add 500 μl of washing solution to each well, and wash the cells three times.

[0040] (9) Prepare the Click reaction solution according to the order and volume of components in the kit instructions. Aspirate the wash solution, add 100 μl of Click reaction solution to each well, shake the 24-well plate gently, and incubate at room temperature in the dark for 30 min.

[0041] (10) Aspirate the Click reaction solution, add 500 μl of washing solution to each well, and wash the cells three times.

[0042] (11) Add 200 μl of diluted 1× Hochest 33342 reaction solution to each well and incubate at room temperature in the dark for 10 min.

[0043] (12) Aspirate the Hoches reaction solution, add 500 μl of washing solution to each well, and wash the cells three times.

[0044] (13) Fluorescence detection was performed using a fluorescence microscope. Azide 488 was green fluorescence with a maximum excitation wavelength of 495 nm and a maximum emission wavelength of 519 nm. Hochest 33342 was blue fluorescence with a maximum excitation wavelength of 346 nm and a maximum absorption wavelength of 460 nm. The experiment was repeated three times.

[0045] 1.2CCK-8 cell proliferation assay

[0046] (1) Fully digest HUVEC and HSF cells, prepare cell suspensions respectively, count the number of cells using a cell counter, and find the appropriate cell inoculation amount after preliminary experiments. Evenly plate 1500 cells in each well of a 96-well plate. Mix the cell suspension from time to time during plating to avoid cell sedimentation, which may result in unequal numbers of cells in each well.

[0047] (2) Culture in a 37°C incubator for 24 hours to allow the cells to adhere. Prepare the required drug concentrations and add them to 96-well plates respectively. The experimental grouping is the same as step (2) in 1.1 above.

[0048] (3) After stimulating the cells for 48 hours, dilute the CCK-8 working solution with DMEM medium (CCK-8: medium = 1:10, v / v), mix well, aspirate the old medium in the test wells, and add 100 ul of the newly prepared CCK-8 medium to each well.

[0049] (4) After the appropriate time of incubation, the OD value at 450 nm was measured on a microplate reader (reference wavelength was 620 nm). The experiment was repeated three times.

[0050] 1.3 Clone formation experiment

[0051] (1) HSF and HUVEC cells in the logarithmic growth phase were digested with trypsin and gently pipetted to prepare single-cell suspensions, and the cell number was counted using a Count Star cell counter.

[0052] (2) Evenly plate 1000 cells in each well of a 6-well plate. Disperse the cells evenly. Make a cross to shake the cells evenly to ensure that there are the same number of cells in each well.

[0053] (3) The 6-well plate with cells was placed in a constant temperature incubator at 37°C and 5% CO2 for several days, and the cell growth and clone formation were observed every day. After the cells in the wells gradually grew into clones consisting of 8-16 cells, the original culture medium was removed. The required drug concentration was prepared and added to the wells to be tested, and the wells were placed back in the incubator for continued cultivation. The experimental grouping was the same as step (2) in 1.1 above.

[0054] (4) After 4 to 5 days of culture, when clones are visible to the naked eye, that is, when the number of cells in the clone cluster reaches 50 to 80, the culture is terminated.

[0055] (5) Aspirate the culture supernatant and carefully wash twice with PBS. Add 1 mL of 4% paraformaldehyde to each well and fix at room temperature for 15 to 20 minutes. Remove the fixative and turn the 6-well plate upside down to dry.

[0056] (6) Add 1 mL of 0.2% crystal violet staining solution to each well and stain for 20 min to stain the clones purple. Recover the crystal violet staining solution and slowly wash away the staining solution with running water until there is no background color interference in the well.

[0057] (7) Allow the 6-well plate to dry naturally, take photos, count, and perform statistics. The experiment was repeated three times.

[0058] 1.4 Transwell experiment

[0059] (1) The cells in logarithmic phase were cultured by replacing the maintenance medium (DMEM medium containing 2% (v / v) serum, the serum was purchased from PAN, Germany) to eliminate the influence of serum.

[0060] (2) HUVEC and HSF cells were digested and cell suspensions were prepared using maintenance medium (DMEM medium with a serum content of 2% (v / v)). The appropriate cell inoculation amount was obtained through preliminary experiments and the number of cells in the suspension was adjusted using a cell counter. The cells were digested with trypsin to prepare cell suspensions.

[0061] (3) Add culture medium containing 10% (v / v) FBS and drugs to the test wells of a 24-well plate (10,000 cells per well), i.e., the lower chamber, wherein the experimental grouping is the same as step (2) in 1.1 above. The culture medium in the lower chamber contains sufficient serum to provide sufficient nutrition and growth factors to induce cell migration.

[0062] (4) Place the Transwell chamber in a 24-well plate. Typically, a Transwell chamber with a pore size of 8 μm is used.

[0063] (5) Distribute the cell suspension evenly in the upper chamber of the Transwell chamber.

[0064] (6) Continue culturing: Culture in a cell culture incubator for 24 to 48 hours. The specific time depends on the results of the preliminary experiment.

[0065] (7) Use a cotton swab (loosen the tip of the cotton swab so that it can reach the corners) to gently wipe away the cells on the upper layer of the chamber.

[0066] (8) Add 500 μl of 4% paraformaldehyde to each well and fix at room temperature for 20 min. Remove the fixative and invert the chamber to air dry.

[0067] (9) Add 0.2% crystal violet staining solution and stain for 20 min. Slowly wash away the staining solution until there is no background color interference.

[0068] (10) Observe the migration of cells in the chamber using a microscope and calculate the number and ratio of migrated cells. The experiment was repeated three times.

[0069] 1.5 Angiogenesis Assay

[0070] (1) When preparing HUVEC cells, the number of passages is a critical factor. When the endothelial cells are between the 2nd and 6th passages, the angiogenesis effect is the best. Passaging too early or too late will affect the experimental results.

[0071] (2) One day in advance, immerse the packaged Matrigel (purchased from Beijing Solebao Technology Co., Ltd.) in ice and place it in a 4°C refrigerator to slowly thaw overnight. The 96-well plate, pipette tip, culture medium and ice box required for the experiment should also be pre-cooled in advance.

[0072] (3) Add 60 μl of matrix gel to the wells to be tested in a 96-well plate. Do not blow the matrix gel during pipetting to avoid generating bubbles and ensure that the matrix gel completely covers the bottom of the well.

[0073] (4) Place the 96-well plate covered with the matrix gel in an incubator at 37°C and 5% CO2 and let it stand for half an hour.

[0074] (5) During the waiting period, HUVEC cells in the logarithmic growth phase were taken, gently washed with PBS, digested with an appropriate amount of trypsin and gently pipetted to prepare a single-cell suspension, and the cell number was adjusted using a Count Star cell counter.

[0075] (6) The solidified 96-well plate covered with matrix gel was taken out. After preliminary experiments, the appropriate cell inoculation amount was found to be 20,000 cells per well. The experimental group was added with final concentrations of 2 μM, 4 μM and 8 μM of Lonicera japonica saponin A, respectively, and the control group was added with 80 ul of cell suspension. The treated well plate was placed back in the incubator.

[0076] (7) Blood vessels begin to form within 2 to 4 hours. Take out the well plate every hour and observe it under a microscope to select the best time to take pictures.

[0077] (8) Quantitative analysis of angiogenesis, including the number of lumen formation, the number of vascular branches, etc. The experiment was repeated three times.

[0078] 1.6 ELISA experiment

[0079] Refer to the instructions of Abmart Human I Collagen ELISA Kit. This kit uses the double antibody sandwich method, and uses purified human I collagen capture antibody to coat the microplate to make a solid phase antibody. Human I collagen is added to the coated microwells in sequence, and then combined with the HRP-labeled detection antibody to form an antibody-antigen-enzyme-labeled antibody complex. After thorough washing, the substrate TMB is added for color development. TMB is converted into blue under the catalysis of HRP enzyme, and converted into the final yellow under the action of acid. The process is as follows:

[0080] (1) Addition of standard samples: Set up standard sample wells and sample wells, and add 50 μL of standard samples of different concentrations to each standard sample well.

[0081] (2) Sample addition: Set up blank wells (blank control wells without sample and enzyme-labeled reagent, and the rest of the steps are the same) and test sample wells. First add 40 μL of sample diluent to the test sample well on the enzyme-labeled plate, and then add 10 μL of the test sample (HSF cell culture supernatant) (the final sample dilution is 5 times). Add the sample to the bottom of the well on the enzyme-labeled plate, try not to touch the well wall, and shake to mix.

[0082] (3) Add enzyme: Add 100 μL of enzyme-labeled reagent to each well, except for the blank well.

[0083] (4) Incubation: Seal the plate with a sealing film and incubate at 37°C for 60 min.

[0084] (5) Liquid preparation: Dilute the 20-fold concentrated washing solution with 20-fold distilled water and set aside.

[0085] (6) Washing: Carefully peel off the sealing film, discard the liquid, spin dry, fill each well with washing solution, let it stand for 30 seconds and then discard. Repeat this process 5 times and pat dry.

[0086] (7) Color development: First add 50 μL of color developer A to each well, then add 50 μL of color developer B, gently shake to mix, and incubate at 37°C in the dark for 15 min.

[0087] (8) Termination: Add 50 μL of stop solution to each well to terminate the reaction (the blue color immediately turns yellow).

[0088] (9) Measurement: Use the blank well as the zero setting, and measure the absorbance (OD value) of each well in sequence at a wavelength of 450 nm. The measurement should be performed within 15 minutes after adding the stop solution. The experiment is repeated three times.

[0089] 2. Honeysuckle saponin A promotes the growth and function of vascular cells and fibroblasts

[0090] 2.1 Chicken embryo chorioallantoic membrane angiogenesis model

[0091] (1) Prepare fertilized chicken embryos (fertilized 4 days ago, purchased from Zhejiang Guangda Poultry Breeding Co., Ltd.), check the quality of the eggs, and clean the surface of the egg shells. Place the chicken embryos horizontally in an incubator for incubation at 37°C and 55% relative humidity, turn them over twice a day, and incubate them until they are 9 days old.

[0092] (2) Take out the chicken embryo and use a light to mark the position of the air chamber and embryo head.

[0093] (3) In an ultra-clean workbench, use sterile ophthalmic forceps and scissors to open a window in the air chamber, and use tweezers to gently peel off the eggshell and clean up the eggshell debris.

[0094] (4) Use a pipette to add 3-5 mL of sterile saline to moisten the shell membrane and make it easier to tear. Then remove the saline.

[0095] (5) Carefully tear off the shell membrane with sterile forceps, taking care not to damage the vascular membrane. Observe the vascular structure and integrity, and remove eggs that are not suitable for the experiment.

[0096] (6) Set up a control group and an experimental group, and add drugs according to the set drug concentration: the experiment was divided into 5 groups, and the experimental groups were added with final concentrations of 0.1 μM, 1 μM, and 10 μM of Lonicera japonica saponin A, respectively; the control group was added with 500 UI bFGF; and the blank control group (Blank, abbreviated as Bk) was not added with drugs.

[0097] (7) Carefully place the control group and the experimental group back into the incubator and continue incubating without stirring.

[0098] (8) Incubate for 11 days and add drugs for 48 hours before observing the results and taking photos. The experiment was repeated three times.

[0099] 2.2 Transgenic zebrafish angiogenesis experiment

[0100] (1) Preparation of test drugs: The test drugs were dissolved in dimethyl sulfoxide (DMSO) and saline (i.e., the drug was first dissolved in DMSO, and then saline was added to the dissolved drug solution for gradient dilution, ensuring that the volume proportion of DMSO was less than 0.1%) to obtain the desired concentration for injection.

[0101] (2) Collection and maintenance of zebrafish eggs: Adult zebrafish CZ55 (y1Tg, Tg (fli1: EGFP) (CZ55 (y1Tg, Tg (fli1: EGFP) was obtained from the National Zebrafish Resource Center, website: http: / / zfish.ihb.ac.cn / Article / 1401.html) were used for breeding to obtain fertilized eggs, which were then maintained in egg water at 28.5°C. The embryos were then transferred to a culture dish containing "blue" water (i.e., embryo culture medium containing double distilled water: NaCl 34.8 g, KCl 1.6 g, CaCl2·2H20 5.8 g, MgC12·6H20 9.78 g, pH 7.2) supplemented with methylene blue to prevent fungal growth. The embryos were maintained in the culture dish until they reached the desired developmental stage.

[0102] (3) Addition of test drugs: At the desired developmental stage, the test drugs were added to the culture water of the developing zebrafish larvae. The experiment was divided into 5 groups, and the experimental groups were added with final concentrations of 0.1 μM, 1 μM and 10 μM of Lonicera japonica saponin A, the control group was added with 500 UI bFGF, and the blank control group (Blank, referred to as Bk) was not added with drugs.

[0103] (4) Observation of angiogenesis: After drug addition, the developing larvae were observed under a microscope to assess angiogenesis. Blood vessels were observed by using a transgenic zebrafish line expressing fluorescent protein in blood vessels. The angiogenic response was quantified by measuring the length, density, and branching of the blood vessels. The experiment was repeated three times.

[0104] 3. Lonicera japonica saponin A promotes skin wound repair in normal mice and diabetic mice

[0105] 3.1 Mouse back skin wound model

[0106] (1) 3% sodium pentobarbital was dissolved in sterile saline and anesthetized by intraperitoneal injection into normal C57BL / 6J mice (purchased from Guangzhou Weitong Lihua Co., Ltd., 6 weeks old) and diabetic BKS-db mice (purchased from Guangdong Yaokang Biotechnology Co., Ltd., 4 weeks old, specific strain name: BKS-Leprem2Cd479 / Gpt, strain type: Knock-out) at 1 mL per kg body weight.

[0107] (2) Place the mouse in a prone position and shave the fur on the back of the mouse with a razor.

[0108] (3) Use a cotton swab to take an appropriate amount of depilatory cream and gently apply it to the back of the mouse. Leave it for 1 minute for better depilatory effect. Use wet gauze to wipe off all depilatory cream and remaining fur.

[0109] (4) Carefully wipe the mouse skin with alcohol cotton balls and iodine.

[0110] (5) Gently lift the skin in the middle of the back, place the mouse on its side, and use a sterile 6 mm punch with ophthalmic scissors to create a full-thickness wound extending through the subcutaneous tissue, including the fascia carnosus. Two symmetrical 6 mm wounds were made on the back of each mouse. Six mice were included in each group.

[0111] (6) Apply glue to one side of the silicone gasket, place it on the wound, and position it so that the wound does not shrink too quickly.

[0112] (7) 30 μL of the drug was dripped onto the surface of two wounds on the back of the mouse; in the normal C57BL / 6J mouse back skin injury model, the experimental groups were 0.1 μM, 1 μM and 10 μM of Lonicera japonica saponin A, the control group was added with 500 UI bFGF, and the blank control group (Blank, referred to as Bk) was normal saline. The drugs were dripped onto the surface of two wounds on the back of the mouse (the same drug was used for the wounds on both sides). In the BKS-db diabetic mouse back skin injury model, the experimental groups were 7.5 μM and 15 μM of Lonicera japonica saponin A, the control group was added with 1000 UI bFGF, and the blank control group (Blank, referred to as Bk) was normal saline.

[0113] (8) Place a ruler under the silicone gasket, measure the wound diameter, and take photos.

[0114] (9) Apply a sterile transparent medical dressing to create a relatively sterile and clean environment, while also fixing the silicone gasket.

[0115] (10) Place the mouse on a heating pad to keep it warm until it is fully awake and return it to its cage.

[0116] (11) The wound repair of the mice back was observed, weighed, and photographed every day. The drugs were administered every other day for a total of 5 times.

[0117] 3.2 H&E staining experiment

[0118] (1) Fixing specimens: The full-thickness skin of the mouse lesions was collected and fixed in 4% paraformaldehyde for a period of time (usually 24 to 48 hours).

[0119] (2) Dehydration and embedding: The fixed tissue specimens were gradiently dehydrated in ethanol solutions of different concentrations (70% ethanol for 1.5 h, 85% ethanol for 1.5 h, 95% ethanol for 2 h, 100% ethanol for 30 min, 100% ethanol for 30 min, 100% ethanol for 30 min (all volume fractions)), then immersed in a transparent agent, and finally embedded in wax.

[0120] (3) Sectioning: Cut the embedded specimen into pieces with a thickness of 3 to 5 microns.

[0121] (4) Dewaxing: Dewax the cut specimen sections with xylene and wash with various levels of ethanol to water.

[0122] (5) Staining: Stain with hematoxylin for 5-20 minutes, rinse with tap water, differentiate with differentiation solution for 30 seconds, soak in tap water for 15 minutes, and place in eosin solution for 2 minutes.

[0123] (6) Dehydration and sealing: The stained sections were gradually dehydrated and transparent, and then sealed with neutral resin and observed under a microscope. The experiment was repeated three times.

[0124] 3.3IHC immunohistochemistry staining experiment

[0125] (1) Tissue preparation: The full-thickness skin of the above-mentioned mouse lesion site is collected and fixed with formalin or 4% paraformaldehyde and then fixed in paraffin. The tissue sample is then sliced ​​with a microtome and placed on a glass slide.

[0126] (2) Dewax the paraffin sections and perform antigen repair on the sections. Antigens can be exposed by methods such as thermal hydrolysis, microwave heating, or enzymatic hydrolysis.

[0127] (3) Block the nonspecific binding sites on the slices and use normal serum or other proteins to seal the samples to avoid false positive results.

[0128] (4) Gently shake off the blocking solution, add the primary antibodies (Anti-αSMA Rabbit pAb and Anti-CD31 Rabbit pAb, both purchased from Wuhan Sevier Biotechnology Co., Ltd.) prepared in proportion to the slices, react specifically with the target molecules, and incubate at 4°C overnight.

[0129] (5) Wash off the unbound primary antibody, add a secondary antibody (HRP labeled) of the same species as the primary antibody (HRP labeled goat anti-rabbit IgG, purchased from BBI Life Sciences Co., Ltd.) to specifically bind to the primary antibody. Drop the secondary antibody on the sample and incubate for a period of time.

[0130] (6) Wash off the unbound secondary antibody, develop color and stain: add freshly prepared DAB color developing solution, control the color development time under a microscope, and the positive color is brown-yellow.

[0131] (7) Re-stain the cell nucleus with hematoxylin for about 3 minutes, and then rinse with tap water. Differentiate with hematoxylin differentiation solution, and then rinse with tap water. Re-bluing with hematoxylin bluing solution, and then rinse with running water.

[0132] (8) Add a drop of neutral resin and seal the slices with a coverslip to protect the slices and for subsequent observation. The experiment was repeated three times.

[0133] 2. Experimental results

[0134] 2.1 Lonicera japonica saponin A promotes the growth and function of vascular cells and fibroblasts

[0135] Vascular endothelial cells play a key role in the tissue repair process, while fibroblasts are essential for tissue repair and growth. These two cell types are responsive to bFGF-FGFR2-mediated growth signals and significantly promote tissue repair and growth. In this study, we used the human vascular endothelial cell line HUVEC and the human fibroblast cell line HSF to investigate the vascular development and cell proliferation effects of Lonicera japonica saponin A. The proliferation capacity of HSF and HUVEC cells was evaluated by EdU and CCK-8 methods. The results showed that as the concentration of Lonicera japonica saponin A increased from 0 μM to 8 μM, the proliferation capacity of both cell types increased significantly. At a concentration of 8 μM, the proliferative effect of Lonicera japonica saponin A was equivalent to that of 500 IU exogenous bFGF ( Figure 1 A. Figure 1 B. Figure 1 C). In addition, a clone formation assay was performed to evaluate the in vitro proliferation capacity of these cells. The results showed that as the concentration of Lonicera japonica saponin A increased, the number of cell clones also increased ( Figure 1 D). The cell migration experiment using Transwell chamber showed that as the concentration of Lonicera japonica saponin A increased, the number of HSF and HUVEC cells passing through the micropores increased, indicating that Lonicera japonica saponin A promoted cell migration ( Figure 1 E). One of the characteristic features of endothelial cells is the formation of vascular lumen. Comparative analysis of their in vitro vascular lumen formation properties showed that Lonicera japonica saponin A enhanced the ability of HUVEC cells to form lumen, suggesting the potential of Lonicera japonica saponin A to promote angiogenesis ( Figure 1 F). Collagen secretion is an important marker of fibroblast function. By detecting the collagen content in the culture supernatant of HSF cells, we observed that the collagen content increased significantly after adding Lonicera japonica saponin A, indicating that Lonicera japonica saponin A induced the secretion of collagen in HSF cells ( Figure 1 G). Overall, the presence of Lonicera japonica saponin A enhanced the proliferation capacity and normal physiological function of HUVEC and HSF cells. These findings indicate that Lonicera japonica saponin A has the ability to regulate cell activities involved in tissue repair.

[0136] 2.2 Lonicera japonica saponin A promotes the growth and function of vascular cells and fibroblasts

[0137] The angiogenic properties of Lonicera japonica saponin A were evaluated in vivo using a chick embryo angiogenesis assay and a zebrafish embryo angiogenesis model. In the chick embryo angiogenesis assay, a concentration gradient of Lonicera japonica saponin A was introduced into the allantoic cyst fluid of 9-day-old chick embryos, and the vascular diameter was measured 48 hours later ( Figure 2 A). The results showed that Lonicera japonica saponin A increased the diameter of blood vessels ( Figure 2 B) Blood vessel area ( Figure 2 C) and the number of vascular branches ( Figure 2 D). The effect of 10 μM Lonicera saponin A in promoting vascular development in chick embryos is comparable to that of 500 IU exogenous bFGF, indicating that it can effectively promote vascular development in chick embryos.

[0138] When evaluating the vascular development of zebrafish embryos, we used the zebrafish model of GFP-labeled vascular endothelial cells previously established by our team to examine and compare the development of the ventral venous plexus and dorsal artery in zebrafish larvae treated with different concentrations of Lonicera japonica saponin A. The results showed that with the increase in the concentration of Lonicera japonica saponin A, the number of vascular branches protruding from the ventral venous plexus and new blood vessels gradually increased, indicating that Lonicera japonica saponin A induced an activated state of vascular growth ( Figure 2 E. Figure 2 F. Figure 2 G). In addition, no significant acute toxicity or teratogenic effects were observed at the highest tested concentration of 10 μM ( Figure 2 H. Figure 2 I).

[0139] 2.3 Lonicera japonica saponin A promotes skin wound repair in normal mice and diabetic mice

[0140] This study used the dorsal skin injury model of normal C57BL / 6J mice and diabetic BKS-db mice (BKS-Leprem2Cd479 / Gpt) to explore the pro-repair effect of Lonicera japonica saponin A. In the C57BL / 6J mouse skin wound model, we created a wound with a diameter of 0.8 cm on the dorsal skin and applied Lonicera japonica saponin A topically on the wound surface every two days starting from the day of wound creation (Day 0). The wound area was photographed and measured every day until complete healing ( Figure 3 A). Statistical analysis showed that all wounds healed completely within 8 days, and the group treated with 500 IU bFGF and the group treated with 10 μM Lonicerae saponin A healed completely within 6 days. The wounds in the groups treated with bFGF and Lonicerae saponin A healed significantly faster than those in the saline (blank) treated group. In the early wound healing stage (Day 0-Day 4), the rate of wound area reduction increased with increasing concentrations of Lonicerae saponin A ( Figure 3 B), the average wound area of ​​the 10μM Lonicera japonica saponin A group was 17.8% smaller than that of the 500IU bFGF group ( Figure 3 C). In the group treated with Lonicera japonica saponin A, the concentration of Lonicera japonica saponin A administered was positively correlated with the rate of wound area reduction ( Figure 3 D). In addition, by monitoring the changes in animal body weight ( Figure 3 E) and alanine aminotransferase (ALT, Figure 3 F) and aspartate aminotransferase (AST, Figure 3 G) serum levels, and the potential acute toxicity of Lonicera japonica saponin A was evaluated, and the results showed that no significant weight changes or changes in liver damage indicators were observed. Subsequently, wound tissue samples were collected and sections from the wound were stained. Hematoxylin and eosin staining (H&E staining) of tissue sections showed that the epidermal and dermal cells of the blank group were smaller and more slender. In contrast, the group treated with 10μM Lonicera japonica saponin A and the group treated with 500IU bFGF showed higher proliferation activity around the wound ( Figure 3 H). The collagen was stained with Sirius red staining, which showed that with the increase of the concentration of Lonicera japonica saponin A, the secretion of collagen in the tissue increased, and the effect of 10 μM Lonicera japonica saponin A treatment was equivalent to that of 500 IU bFGF ( Figure 3 I). Immunohistochemistry (IHC) staining using CD31 monoclonal antibody showed that in the wounds of the group treated with Lonicera japonica saponin A, the number of vascular endothelial cells increased with the increase of Lonicera japonica saponin A ( Figure 3 J). These results indicate that Lonicera japonica saponin A can effectively promote wound healing in C57BL / 6J mice and play a role in promoting angiogenesis and collagen secretion during tissue repair.

[0141] In the BKS-db diabetic mouse model, we used the same protocol as the normal skin wound model to treat the mice with different concentrations of Lonicera japonica saponin A ( Figure 4 A). On day 8, the wound area of ​​the 15μM Lonicerae saponin A group was reduced by 22.3% compared with the 1000IU bFGF group, indicating that Lonicerae saponin A is more effective than bFGF in promoting early repair of refractory diabetic wounds ( Figure 4 B. Figure 4 C. Figure 4 D). During the entire experimental period, administration of Lonicera japonica saponin A did not significantly affect the body weight of diabetic mice, indicating that no significant acute toxicity was observed in this mouse model ( Figure 4 E). Histological analysis of wound skin tissue by H&E staining showed thickening of the epidermis and dermis in the Lonicera japonica saponin A-treated group and the bFGF group ( Figure 4 F). Masson staining showed that collagen staining in the group treated with Lonicera japonica saponin A increased significantly, indicating that Lonicera japonica saponin A promoted the secretion of collagen in the wound site ( Figure 4G). Immunohistochemistry (IHC) of fibroblasts using anti-α-SMA monoclonal antibody showed that the number of fibroblasts in the epidermis and dermis of the 15μM Lonicera japonica saponin A group and bFGF group was greater than that of the blank group ( Figure 4 H). Statistical analysis also showed that the number of CD31-positive vascular endothelial cells in the 15 μM Lonicerae glabra saponin A treatment group was significantly increased compared with the blank group, indicating that Lonicerae glabra saponin A enhanced the activity of vascular neointimal membrane ( Figure 4 I). These findings suggest that L. glauca saponin A promotes fibroblast proliferation, angiogenesis, and wound repair in diabetic refractory skin lesions.

[0142] In conclusion, Lonicera japonica saponin A significantly increased the healing rate of normal skin wounds and refractory diabetic wounds, especially in the early repair stage of the wound.

[0143] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Application of Lonicera japonica saponin A in the preparation of products that promote skin wound repair and regeneration.

2. The use according to claim 1, characterized in that: The promotion of skin wound repair and regeneration includes promoting the repair and regeneration of skin cells after wounding, and promoting the repair and regeneration of chronic wounds.

3. The use according to claim 1, characterized in that: The chronic wounds include refractory diabetic wounds.

4. The use according to claim 1, characterized in that: The lonicerae griseae saponin A can promote the repair and regeneration of skin wounds by promoting the proliferation and migration of fibroblasts, the proliferation and migration of vascular endothelial cells, the lumen formation of vascular endothelial cells, and the secretion of type I collagen by fibroblasts.

5. The use according to claim 1, characterized in that: The use concentration of the honeysuckle saponin A is 0.1-15 μmol / L.

6. The use according to claim 1, characterized in that: The products include medical products, skin care products or cosmetics.

Citation Information

Patent Citations

  • Beverage capable of dispelling alcohol effect and protecting liver and preparation method of beverage

    CN105380051A

  • Dipsacus asper CYP450 type DaCYP085 monooxygenase gene and application thereof

    CN118048369A

  • Lonicera macranthoides active total saponin extract and its preparing method and use

    CN1821262A